|Budget Amount *help
¥17,680,000 (Direct Cost: ¥13,600,000、Indirect Cost: ¥4,080,000)
Fiscal Year 2009: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2008: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2007: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
We have demonstrated that the anti-CCR4 mAb reduces the number of Treg cells among TIL in an in vivo NOG mouse model (bearing human tumor & engrafted with human immune cells). These results indicate that use of anti-CCR4 mAb could represent a novel strategy for the treatment not only of Hodgkin lymphoma, but also many other types of cancer by overcoming suppressive effects of Treg cells on the host's immune response to tumor cells. In the near future, the efficacy of the anti-CCR4 mAb in the latter context will also be established in clinical trials in humans.